WO2009142968A3 - Valproic acid salts - Google Patents

Valproic acid salts Download PDF

Info

Publication number
WO2009142968A3
WO2009142968A3 PCT/US2009/043701 US2009043701W WO2009142968A3 WO 2009142968 A3 WO2009142968 A3 WO 2009142968A3 US 2009043701 W US2009043701 W US 2009043701W WO 2009142968 A3 WO2009142968 A3 WO 2009142968A3
Authority
WO
WIPO (PCT)
Prior art keywords
valproic acid
acid salts
salts
compositions
methods
Prior art date
Application number
PCT/US2009/043701
Other languages
French (fr)
Other versions
WO2009142968A2 (en
Inventor
Cyrus Harmon
David Myles
Original Assignee
Olema Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals, Inc. filed Critical Olema Pharmaceuticals, Inc.
Publication of WO2009142968A2 publication Critical patent/WO2009142968A2/en
Publication of WO2009142968A3 publication Critical patent/WO2009142968A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to therapeutically acceptable salts of valproic acid, such as tamoxifen valproic acid salt, compositions comprising salts of valproic acid, and methods of treating cancer with valproic acid salts. Compositions according to the invention include pharmaceutical formulations of valproic acid salts. The invention therefore provides methods of treatment and pharmaceutical compositions.
PCT/US2009/043701 2008-05-20 2009-05-13 Valproic acid salts WO2009142968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5469108P 2008-05-20 2008-05-20
US61/054,691 2008-05-20

Publications (2)

Publication Number Publication Date
WO2009142968A2 WO2009142968A2 (en) 2009-11-26
WO2009142968A3 true WO2009142968A3 (en) 2010-01-14

Family

ID=41340785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/043701 WO2009142968A2 (en) 2008-05-20 2009-05-13 Valproic acid salts

Country Status (1)

Country Link
WO (1) WO2009142968A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3846789A4 (en) * 2018-09-05 2022-05-25 National Centre For Cell Science A novel anti-cancer combination and a method of therapy using the combination

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788063A (en) * 1984-08-14 1988-11-29 State Of Israel, Represented By Prime Minister's Office Israel Institute For Biological Research Drug delivery system
US5558877A (en) * 1993-12-23 1996-09-24 Roussel Uclaf Method and device for treatment of cancer
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788063A (en) * 1984-08-14 1988-11-29 State Of Israel, Represented By Prime Minister's Office Israel Institute For Biological Research Drug delivery system
US5558877A (en) * 1993-12-23 1996-09-24 Roussel Uclaf Method and device for treatment of cancer
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer

Also Published As

Publication number Publication date
WO2009142968A2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CA2871471C (en) Dna-pk inhibitors
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
IN2012DN02081A (en)
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
EP2418945A4 (en) Mineral salt-sulfonic acid compositions and methods of use
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
IN2012MN02591A (en)
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2431366A4 (en) New chlorine e6-folic acid conjugated compound, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
NZ597510A (en) NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2013040227A3 (en) Therapeutic compounds
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012162513A3 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
SMT201300112B (en) Citrate salt of 9E-15- (2-pyrrolidin-1-yl-ethoxy) -7,12,25-triossa-19,21,24-triaza-tetracycloÄ18.3.1.1 (2,5) .1 (14, 18) Üesacos a-1 (24), 2,4,9,14,16,18 (26), 20,22-nonaene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751197

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751197

Country of ref document: EP

Kind code of ref document: A2